Company to Highlight the Role of Precision Diagnostics in Transforming Rare and Undiagnosed Disease CareHOUSTON, Aug. 25, ...

The candidates are sourced from Arnatar’s next-gen RNA discovery engine, dubbed DARGER for dual-functional antisense RNA for ...

Arnatar is developing ART4, an antisense oligonucleotide that ups the expression of its target protein to treat a rare ...

A peer-reviewed study published in Scientific Reports, part of the Nature Portfolio, demonstrates a novel bioinformatic method for identifying messenger RNA (mRNA) biomarkers in stool that show high ...

After a person survives a heart attack, the heart has a brief window of time in which it can heal if the right circumstances ...

Tuberculosis (TB) is the world's deadliest infectious disease—and one of the hardest to cure. Standard treatment requires a ...

A close associate of the HHS secretary claims the U.S. government will soon pull COVID-19 mRNA jabs from the market.

Tuberculosis (TB) is the world's deadliest infectious disease—and one of the hardest to cure. Standard treatment requires a ...

Arnatar Therapeutics, a biotechnology company pioneering RNA-based therapies for severe and underserved diseases, emerges from stealth today and announces that the U.S. Food and Drug Administration ...

While the process via which different types of neurons are produced, also known as neurogenesis, has been the focus of ...

Major depressive disorder (MDD) is one of the most common psychiatric illnesses worldwide, but its molecular causes have ...